HH Biotechnology Holdings Company (HHBT) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.00 means the share price is 0.00 times one year of earnings per share. Beta 4.45: the stock has moved about 345% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHH Biotechnology Holdings Company (HHBT) trades at $0.0001. HH Biotechnology Holdings Company focuses on health and green industries, specifically the planting and supply of macadamia nuts. Sector: Real estate.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for HHBT: HHBT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
HH Biotechnology Holdings Company (HHBT) Real Estate Portfolio & Strategy
HH Biotechnology Holdings Company, operating in the real estate services sector, cultivates and supplies macadamia nuts for diverse applications. With a 31.0% profit margin, the company focuses on health and green industries, distinguishing itself through its agricultural focus within the real estate landscape.
What Is the Investment Thesis for HHBT?
HH Biotechnology Holdings Company presents a unique investment proposition within the real estate services sector due to its focus on macadamia nut cultivation. The company's 31.0% profit margin indicates operational efficiency, while its 29.5% gross margin reflects the profitability of its core business. Key value drivers include the increasing demand for macadamia nuts in various industries and the company's established presence in the Chinese market. Potential catalysts include expansion into new geographic regions and diversification of product offerings. However, investors may want to evaluate the high beta of 4.45, indicating significant volatility, and the absence of dividends, which may deter income-seeking investors. The company's success hinges on its ability to scale production, manage costs, and navigate the competitive landscape.
Based on FMP financials and quantitative analysis
HHBT Key Highlights
Profit Margin of 31.0% indicates strong operational efficiency.
- Gross Margin of 29.5% reflects the profitability of macadamia nut cultivation.
- Beta of 4.45 suggests high volatility compared to the market.
- Focus on health and green industries aligns with growing consumer trends.
- Headquartered in Shenyang, China, providing access to a large and growing market.
Who Are HHBT's Competitors?
HHBT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| UK Ucommune International Ltd | $1.91 | -2.05% | — | |
| LRHC La Rosa Holdings Corp. | $1.58 | +1.28% | — | |
| DUO Fangdd Network Group Ltd. | $0.62 | -3.90% | $5.16M | 33 5-pillar |
| AIRE reAlpha Tech Corp. | $1.33 | +0.76% | $7.08M | — |
| GYRO Gyrodyne, LLC | $4.50 | -1.31% | $10.0M | 44 5-pillar |
| FTHM Fathom Holdings Inc. | $0.23 | -32.27% | $11.1M | — |
| WETH WETH | $0.99 | -0.70% | $11.9M | 55 5-pillar |
| OPAD Offerpad Solutions Inc. | $3.05 | -6.30% | $14.9M | 30 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HHBT's Key Strengths?
Specialization in macadamia nut cultivation.
- Established presence in the Chinese market.
- Focus on health and green industries.
- Profit Margin of 31.0%.
What Are HHBT's Weaknesses?
High beta of 4.45.
- Lack of dividend payments.
- Limited geographic diversification.
- Small number of employees (121).
What Are the Key Risks for HHBT?
Competition from larger agricultural companies.
- Fluctuations in macadamia nut prices.
- Changes in consumer preferences.
- Economic downturns.
- Limited financial disclosure due to OTC Other listing.
What Are HHBT's Competitive Advantages?
- Specialization in macadamia nut cultivation.
- Established presence in the Chinese market.
- Focus on health and green industries.
- Potential for sustainable farming practices.
What Does HHBT Do?
HH Biotechnology Holdings Company, originally incorporated in 1987 as Great China International Holdings, Inc., transitioned to its current name in August 2016 to reflect its focus on health and green industries. Headquartered in Shenyang, People's Republic of China, the company specializes in the cultivation and supply of macadamia nuts. These nuts are utilized across various sectors, including food, cooking oils, healthy products, toiletries, and cosmetics. The company's operations are centered around providing high-quality macadamia nuts to meet the growing demand for natural and healthy ingredients. With 121 employees, HH Biotechnology Holdings Company aims to capitalize on the increasing consumer interest in health-conscious products and sustainable practices. The company's strategic shift towards macadamia nut production positions it within the broader agricultural sector, aligning with the rising global demand for plant-based ingredients and natural resources.
What Products and Services Does HHBT Offer?
- Cultivates macadamia nuts.
- Supplies macadamia nuts to food manufacturers.
- Provides macadamia nuts for cooking oil production.
- Offers macadamia nuts for healthy product formulations.
- Supplies macadamia nuts for toiletries and cosmetics.
- Focuses on health and green industries.
How Does HHBT Make Money?
- Cultivation and harvesting of macadamia nuts.
- Sale of macadamia nuts to various industries.
- Revenue generation through product sales.
- Focus on sustainable and environmentally friendly practices.
What Industry Does HHBT Operate In?
HH Biotechnology Holdings Company operates within the real estate services sector, with a specific focus on agricultural activities related to macadamia nut production. The global macadamia market is experiencing growth driven by increasing demand for healthy snacks, plant-based ingredients, and natural cosmetics. The competitive landscape includes agricultural companies, food producers, and cosmetic manufacturers. HH Biotechnology Holdings Company differentiates itself through its specialization in macadamia nuts and its presence in the Chinese market. The company's success depends on its ability to compete with larger agricultural players and capitalize on the growing demand for macadamia nuts in various industries.
Who Are HHBT's Key Customers?
- Food manufacturers.
- Cooking oil producers.
- Healthy product companies.
- Toiletries and cosmetics manufacturers.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
HH Biotechnology Holdings Company operates in the Real Estate - Services industry within the Real Estate sector. It is headquartered in Shenyang, CN. The company is led by CEO Sheng Jiang. HHBT has traded publicly since 2005.
Key Financial Metrics
Return on equity for HH Biotechnology Holdings Company stands at 8.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.3%, showing how much profit it generates from its asset base. HHBT trades at a trailing price-to-earnings ratio of 0.00, below the Real Estate sector average of ~30.50x. A current ratio of 2.32 indicates the company holds enough short-term assets to cover its near-term obligations.
HHBT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
HHBT Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
HHBT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HHBT.
Price Targets
Wall Street price target analysis for HHBT.
HHBT MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HHBT; grades run from A+ (80-100) to F (below 30).
Leadership: Sheng Jiang
CEO
Sheng Jiang is the CEO of HH Biotechnology Holdings Company, overseeing the company's operations in the health and green industries. His background includes experience in managing teams and driving strategic initiatives. He is responsible for the company's overall performance and growth. With a focus on sustainable practices and innovation, Sheng Jiang aims to position HH Biotechnology Holdings Company as a leader in the macadamia nut industry.
Track Record: Under Sheng Jiang's leadership, HH Biotechnology Holdings Company has focused on expanding its macadamia nut cultivation and supply operations. Key milestones include increasing production capacity and establishing partnerships with food and cosmetic companies. His strategic decisions have contributed to the company's growth and profitability. He manages 121 employees.
HHBT OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that HH Biotechnology Holdings Company may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low liquidity and high price volatility.
- Lack of regulatory oversight.
- Potential for fraud and manipulation.
- Difficulty in obtaining reliable information.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal issues.
- Monitor trading volume and price activity.
- Consult with a financial advisor.
- Company has been in business since 1987.
- Focus on a specific niche market (macadamia nuts).
- Presence of a CEO (Sheng Jiang).
- 121 employees suggest some scale of operations.
- Profit margin of 31.0% indicates some financial viability.
HHBT Real Estate Stock FAQ
What do analysts say about HHBT stock?
Key valuation metrics to consider include the company's profit margin of 31.0% and gross margin of 29.5%. Growth considerations include the increasing demand for macadamia nuts in various industries and the company's potential for expansion into new markets.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on OTC Other stocks.